Asterias Biotherapeutics (AST) Misses Q1 EPS by 13c

Asterias Biotherapeutics (NYSE: AST) reported Q1 EPS of ($0.27), $0.13 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $870 thousand.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Chagee Holdings (CHA) Tops Q2 EPS by 3c
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook